U.S. markets close in 1 hour 8 minutes

Poxel S.A. (PXXLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
7.700.00 (0.00%)
As of 11:19AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.70
Open7.70
Bid0.00 x 0
Ask0.00 x 0
Day's Range7.70 - 7.70
52 Week Range6.03 - 15.35
Volume1,494
Avg. Volume58
Market Cap193.16M
Beta (5Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-0.26
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2020
    Business Wire

    Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2020

    POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2020.

  • Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the French Government
    Business Wire

    Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the French Government

    POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that it has received financing approval from BNP Paribas, Bpifrance and CIC Lyonnaise de Banque for a total of EUR 6 million in the form of state-guaranteed loans (Prêts Garantis par l’Etat, or PGE in France) in the context of the COVID-19 pandemic.

  • Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator
    Business Wire

    Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator

    POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced positive top-line results for STAMP-NAFLD, the PXL770 Phase 2a trial. The Phase 2a trial was a 12-week, randomized, parallel group study, in 120 presumed NASH patients with or without diabetes. PXL770 is a first-in-class, oral direct adenosine monophosphate-activated protein kinase (AMPK) activator. AMPK is a master regulator of several important metabolic pathways, including lipid metabolism, glucose control and inflammation, and is a novel target for NASH and a range of other chronic and rare metabolic diseases.